-
![4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES](/abs-image/US/2010/08/12/US20100204119A1/abs.jpg.150x150.jpg)
1.发明申请4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES 审中-公开4-氨基-5-氧代-7,8-二氢吡啶并[5,4-F] [1,4]氧杂环己烯-6（5H） - 苯基衍生物公开(公告)号：US20100204119A1
公开(公告)日：2010-08-12
申请号：US12697658
申请日：2010-02-01
IPC分类号： A61K38/16 , C07D498/04 , A61K31/553 , A61P3/10 , A61P3/04 , A61K31/56
CPC分类号： C07D498/04 , A61K31/553 , A61K45/06 , A61K2300/00
摘要： The invention provides compounds of Formula (I), wherein R1, R2a, R2b, R3, m and A are as defined herein, as well as compositions thereof and methods for treating a disease, condition or disorder that is modulated by the inhibition of the diacylglycerol O-acyltransferase 1 (DGAT-1) enzyme by administering the compounds of the present invention and/or compositions thereof.
摘要翻译： 本发明提供式（I）化合物，其中R 1，R 2a，R 2b，R 3，m和A如本文所定义，以及其组合物和治疗疾病，病症或病症的方法，其通过抑制 二酰基甘油O-酰基转移酶1（DGAT-1）酶，通过施用本发明的化合物和/或其组合物。
-
![4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES](/abs-image/US/2010/08/05/US20100197591A1/abs.jpg.150x150.jpg)
2.发明申请4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES 审中-公开4-氨基-7,8-二氢吡啶并[4,3-d]嘧啶-5（6H） - 酮衍生物公开(公告)号：US20100197591A1
公开(公告)日：2010-08-05
申请号：US12697715
申请日：2010-02-01
IPC分类号： A61K31/519 , C07D471/04 , A61P31/04 , A61P31/10 , A61K31/536 , A61K31/55 , A61K38/16 , A61K31/4985 , A61P3/10
CPC分类号： C07D471/04
摘要： The invention provides compounds of the general Formula (I) where R1, R2, and A are defined herein, as well as the preparation, compositions and uses thereof.
摘要翻译： 本发明提供了其中R 1，R 2和A在本文中定义的通式（I）的化合物，以及其制备，组合物和用途。
-
公开(公告)号：US06723744B2
公开(公告)日：2004-04-20
申请号：US10255180
申请日：2002-09-24
IPC分类号： A61K3140
CPC分类号： C07D209/42
摘要： A compound of the formula wherein W, R1, R2, R3, R4, R5, R6, R7, R8 and R13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.
摘要翻译： 式R w，R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8和R 13的化合物 >如本文所定义，可用于治疗肥胖症，超重病症，高脂血症，青光眼，心律失常，皮肤病症，甲状腺疾病，甲状腺功能减退，甲状腺癌和相关疾病以及疾病如糖尿病，动脉粥样硬化，高血压，冠心病 充血性心力衰竭，高胆固醇血症，抑郁症，骨质疏松症和脱发。
-
公开(公告)号：US07202275B2
公开(公告)日：2007-04-10
申请号：US11125710
申请日：2005-05-10
IPC分类号： A61K31/215 , A61K31/235 , A61K31/24 , A61K37/44
CPC分类号： C07C233/25 , C07C235/16 , C07C235/80 , C07C311/29 , C07C317/22 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07D209/46
摘要： The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders
摘要翻译： 本发明涉及新型甲状腺受体配体，更具体地涉及式I的丙氨酸及其衍生物，其可用于治疗肥胖症，超重病症，高脂血症，青光眼，心律失常，皮肤病，甲状腺疾病， 甲状腺功能减退，甲状腺癌及相关疾病，如糖尿病，动脉粥样硬化，高血压，冠心病，充血性心力衰竭，高胆固醇血症，抑郁症，骨质疏松症和脱发。 本发明还提供了用于治疗这些疾病和病症的方法，药物组合物和试剂盒
-
公开(公告)号：US06924310B2
公开(公告)日：2005-08-02
申请号：US10683372
申请日：2003-10-10
IPC分类号： A61K31/195 , C07C233/25 , C07C235/16 , C07C235/80 , C07C311/29 , C07C311/37 , C07C317/22 , C07D209/46 , C07C311/00
CPC分类号： C07C233/25 , C07C235/16 , C07C235/80 , C07C311/29 , C07C317/22 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07D209/46
摘要： The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.
摘要翻译： 本发明涉及新型甲状腺受体配体，更具体地涉及式I的丙氨酸及其衍生物，其可用于治疗肥胖症，超重病症，高脂血症，青光眼，心律失常，皮肤病，甲状腺疾病， 甲状腺功能减退，甲状腺癌及相关疾病，如糖尿病，动脉粥样硬化，高血压，冠心病，充血性心力衰竭，高胆固醇血症，抑郁症，骨质疏松症和脱发。 本发明还提供了用于治疗这些疾病和病症的方法，药物组合物和试剂盒。
-
公开(公告)号：US06664291B2
公开(公告)日：2003-12-16
申请号：US09819283
申请日：2001-03-28
IPC分类号： A61K31235
CPC分类号： C07C233/25 , C07C235/16 , C07C235/80 , C07C311/29 , C07C317/22 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07D209/46
摘要： The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.
摘要翻译： 本发明涉及新型甲状腺受体配体，更具体地涉及式I的丙氨酸及其衍生物，其可用于治疗肥胖症，超重病症，高脂血症，青光眼，心律失常，皮肤病，甲状腺疾病， 甲状腺功能减退，甲状腺癌及相关疾病，如糖尿病，动脉粥样硬化，高血压，冠心病，充血性心力衰竭，高胆固醇血症，抑郁症，骨质疏松症和脱发。 本发明还提供了用于治疗这些疾病和病症的方法，药物组合物和试剂盒。
-
公开(公告)号：US06441015B2
公开(公告)日：2002-08-27
申请号：US09767771
申请日：2001-01-23
IPC分类号： A61F3141
CPC分类号： C07D257/04
摘要： The present invention relates to tetrazole compounds of Formula I, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs. The invention also relates to compositions comprising the tetrazole compounds and to methods of treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, and osteoporosis using the tetrazole compounds.
摘要翻译： 本发明涉及式I的四唑化合物，立体异构体，其药学上可接受的盐和前药，以及前药的药学上可接受的盐。本发明还涉及包含四唑化合物的组合物和治疗肥胖症，糖尿病，动脉粥样硬化，高血压的方法 冠状动脉心脏病，高胆固醇血症，高脂血症，甲状腺疾病，甲状腺癌，甲状腺机能减退，抑郁症，青光眼，心律失常，充血性心力衰竭和使用四唑化合物的骨质疏松症。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.033 秒)
